芒果视频下载

成立于1998年，知名阿膠品牌，以藥業/酒業為主導，集研發/生產/經營/投資/管理于一體的綜合性集團公司，產品涵蓋了中西藥制劑/生物制藥/原料藥/保健食品等品類

1998年成立的輔仁藥業集團，是一家以藥業、酒業為主導，集研發、生產、經營、投資、管理于一體的綜合性集團公司。集(ji)(ji)(ji)團(tuan)(tuan)囊括河(he)(he)南(nan)輔(fu)仁(ren)堂制藥(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、河(he)(he)南(nan)輔(fu)仁(ren)懷慶堂制藥(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、開(kai)封制藥(yao)(yao)(yao)（集(ji)(ji)(ji)團(tuan)(tuan)）有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、開(kai)封豫(yu)港(gang)制藥(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、開(kai)藥(yao)(yao)(yao)集(ji)(ji)(ji)團(tuan)(tuan)（開(kai)魯(lu)）制藥(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、河(he)(he)南(nan)同源制藥(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、輔(fu)仁(ren)醫(yi)藥(yao)(yao)(yao)科技(ji)開(kai)發(fa)(fa)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、輔(fu)仁(ren)藥(yao)(yao)(yao)業集(ji)(ji)(ji)團(tuan)(tuan)醫(yi)藥(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、輔(fu)仁(ren)藥(yao)(yao)(yao)業集(ji)(ji)(ji)團(tuan)(tuan)熙德隆腫瘤藥(yao)(yao)(yao)品有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、北京遠策(ce)藥(yao)(yao)(yao)業有(you)(you)限(xian)(xian)(xian)(xian)責任(ren)公(gong)(gong)(gong)司(si)(si)、北京輔(fu)仁(ren)瑞輝(hui)生物(wu)醫(yi)藥(yao)(yao)(yao)研究(jiu)院、上海輔(fu)仁(ren)醫(yi)藥(yao)(yao)(yao)研發(fa)(fa)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、鄭州遠策(ce)生物(wu)制藥(yao)(yao)(yao)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、河(he)(he)南(nan)省宋河(he)(he)酒業股(gu)份(fen)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)及上市公(gong)(gong)(gong)司(si)(si)輔(fu)仁(ren)藥(yao)(yao)(yao)業集(ji)(ji)(ji)團(tuan)(tuan)制藥(yao)(yao)(yao)股(gu)份(fen)有(you)(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)等(deng)多(duo)家全資、控股(gu)子公(gong)(gong)(gong)司(si)(si)。

集團產(chan)品(pin)涵蓋(gai)了中西藥(yao)制劑、生物制藥(yao)、原料藥(yao)、保健食(shi)品(pin)等多(duo)個(ge)門類(lei)。2006年(nian)，隨(sui)著(zhu)河南輔(fu)仁(ren)堂制藥(yao)有限(xian)公(gong)司成功實現(xian)上市，資(zi)(zi)本的力量(liang)不僅把輔(fu)仁(ren)推向一個(ge)飛速發(fa)展時(shi)期(qi)，其行(xing)業(ye)地位(wei)亦(yi)逐步提升。2017年(nian)12月29日(ri)，輔(fu)仁(ren)藥(yao)業(ye)重大資(zi)(zi)產(chan)重組(zu)成功，把集團優質(zhi)資(zi)(zi)產(chan)——開(kai)封制藥(yao)（集團）有限(xian)公(gong)司置入輔(fu)仁(ren)藥(yao)業(ye)，使輔(fu)仁(ren)藥(yao)業(ye)跨入一個(ge)新的發(fa)展階段(duan)。

“品(pin)種(zhong)為核心，并購為主線”的(de)早期發展戰略讓輔仁(ren)藥業(ye)集(ji)團(tuan)(tuan)的(de)產(chan)(chan)能和產(chan)(chan)品(pin)線在(zai)很短時間(jian)內飛速發展。迄今，輔仁(ren)藥業(ye)集(ji)團(tuan)(tuan)已擁有水針劑(ji)、凍干(gan)粉針劑(ji)、口服固體(ti)制(zhi)劑(ji)等20多個(ge)(ge)(ge)(ge)劑(ji)型，1000余(yu)個(ge)(ge)(ge)(ge)品(pin)種(zhong)；制(zhi)劑(ji)綜合產(chan)(chan)能位居全國制(zhi)藥行業(ye)前(qian)茅(mao)。2017新版(ban)(ban)(ban)醫保目(mu)錄輔仁(ren)藥業(ye)集(ji)團(tuan)(tuan)共(gong)入(ru)選578個(ge)(ge)(ge)(ge)品(pin)種(zhong)，較(jiao)2009版(ban)(ban)(ban)目(mu)錄增加(jia)品(pin)種(zhong)165個(ge)(ge)(ge)(ge)，增幅(fu)39.95%，其中甲類(lei)入(ru)選364個(ge)(ge)(ge)(ge)，增幅(fu)42.754%，乙類(lei)入(ru)選214個(ge)(ge)(ge)(ge)，增幅(fu)35.44%。在(zai)國家衛健委正式發布《國家基本(ben)藥物目(mu)錄（2018年版(ban)(ban)(ban)）》中，輔仁(ren)藥業(ye)集(ji)團(tuan)(tuan)共(gong)有阿莫西林克(ke)拉(la)維酸鉀干(gan)混懸劑(ji)、奧美拉(la)唑腸(chang)溶(rong)膠囊、注射用重組人干(gan)擾素(su)α2b等262個(ge)(ge)(ge)(ge)品(pin)規榜(bang)上(shang)有名，較(jiao)2012版(ban)(ban)(ban)目(mu)錄增加(jia)75個(ge)(ge)(ge)(ge)，增幅(fu)40.11%，成為全國入(ru)選品(pin)種(zhong)較(jiao)多的(de)制(zhi)藥企業(ye)之一。

輔仁(ren)藥業(ye)(ye)集(ji)團(tuan)一直遵循(xun)“濟世(shi)(shi)藥為輔、惠民志(zhi)在仁(ren)”的(de)企(qi)業(ye)(ye)理(li)念(nian)，始終貫徹“產量(liang)讓(rang)位(wei)于(yu)質(zhi)量(liang)、成本讓(rang)位(wei)于(yu)質(zhi)量(liang)”的(de)質(zhi)量(liang)管理(li)方針，本著“和而不同、化繁為簡(jian)、務實創新、濟世(shi)(shi)惠民”的(de)企(qi)業(ye)(ye)價值觀，把“做一家實體型(xing)、科技(ji)型(xing)、國際型(xing)企(qi)業(ye)(ye)”作為自己(ji)的(de)企(qi)業(ye)(ye)定位(wei)，兼容并蓄，尊重(zhong)規(gui)律，踐行(xing)規(gui)則(ze)。

在企(qi)業(ye)(ye)并(bing)購的(de)同(tong)時，輔仁藥(yao)業(ye)(ye)集團(tuan)投(tou)入巨(ju)資(zi)加強企(qi)業(ye)(ye)創(chuang)新(xin)(xin)平臺(tai)建設(she)，戰(zhan)略性布(bu)局(ju)鄭(zheng)州(zhou)技術研(yan)(yan)(yan)發(fa)和國際化(hua)(hua)合(he)作(zuo)及產業(ye)(ye)化(hua)(hua)服務平臺(tai)、北京創(chuang)新(xin)(xin)研(yan)(yan)(yan)發(fa)平臺(tai)、上海醫(yi)藥(yao)研(yan)(yan)(yan)發(fa)創(chuang)新(xin)(xin)國際合(he)作(zuo)平臺(tai)、美國新(xin)(xin)澤(ze)西(xi)、費城(cheng)研(yan)(yan)(yan)發(fa)平臺(tai)四大研(yan)(yan)(yan)發(fa)創(chuang)新(xin)(xin)平臺(tai)，以及中(zhong)醫(yi)藥(yao)大數據(ju)及人工智能中(zhong)醫(yi)研(yan)(yan)(yan)發(fa)平臺(tai)，更將在小分子化(hua)(hua)學藥(yao)、大分子生物藥(yao)研(yan)(yan)(yan)發(fa)和中(zhong)醫(yi)藥(yao)傳(chuan)承創(chuang)新(xin)(xin)方(fang)向(xiang)同(tong)時發(fa)力，開辟(pi)以研(yan)(yan)(yan)發(fa)驅動(dong)創(chuang)新(xin)(xin)的(de)發(fa)展新(xin)(xin)路徑。

目前，輔(fu)仁(ren)藥業(ye)集(ji)團支持(chi)創(chuang)(chuang)新(xin)研(yan)發(fa)面積達11.3萬(wan)平(ping)方(fang)米，研(yan)發(fa)創(chuang)(chuang)新(xin)隊伍近1500人。同(tong)時，秉承(cheng)“中國(guo)市場、輔(fu)仁(ren)平(ping)臺、全球資源”的(de)發(fa)展策略，輔(fu)仁(ren)藥業(ye)集(ji)團實現(xian)了從“百姓藥、輔(fu)仁(ren)造”到“創(chuang)(chuang)新(xin)藥、輔(fu)仁(ren)造”的(de)可持(chi)續(xu)發(fa)展跨越，為(wei)客戶(hu)及整個(ge)社(she)會創(chuang)(chuang)造價值，健康中國(guo)，服(fu)務(wu)世界。